COMMUNIQUÉS West-GlobeNewswire

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
03/09/2025
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless [...]
Expert on Sham Peer Review Discusses Tactic of Not Allowing Doctor’s Attorney to Speak, in the Journal of American Physicians and Surgeons
02/09/2025
TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- A physician who is a victim of sham peer review at his hospital may be shocked to learn that some medical staff bylaws prohibit the physician’s attorney from speaking at [...]
SYNDEO Medical Announces Multi-Year Exclusive Distribution Agreement for Bearpac’s Passio™ Pump Drainage System
02/09/2025
ZAVENTEM, Belgium, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SYNDEO Medical today announced a multi-year exclusive distribution agreement with Bearpac Medical for the Passio™ Pump Drainage System, granting SYNDEO exclusive [...]
Evidence for ‘Chemtrails’ Examined in the Journal of American Physicians and Surgeons
02/09/2025
TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The “chemtrails” theory gained prominence in the Make America Healthy Again (MAHA) movement, leading to the enactment of related legislative measures. In the fall issue [...]
The Implications of Artificial Intelligence (AI) for Medicine Discussed in the Journal of American Physicians and Surgeons
02/09/2025
TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) is envisioned by many to be the future of medicine, and it is critical to understand its implications and the background of technocracy, [...]
Harms from Modified mRNA COVID-19 Vaccines Discussed in the Journal of American Physicians and Surgeons
02/09/2025
TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Experience to date indicates that modified mRNA COVID-19 vaccines can disrupt every body system, and that urgent scrutiny and accountability are needed, write Andrew [...]
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
02/09/2025
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed [...]
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
02/09/2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
02/09/2025
WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]
HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results
02/09/2025
Highlights of the second quarter include: Revenue of $325.8 million, an increase of 9% compared to $299.9 million in Q2 FY25. Net income of $59.9 million, an increase of 67% compared to $35.8 million in Q2 FY25, with [...]
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
02/09/2025
COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual [...]
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2025
ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly- [...]
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
02/09/2025
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27 th [...]
Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
Berkeley, Calif, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the [...]
Lyell Immunopharma Announces Participation in September Investor Conferences
02/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell [...]
STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
02/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2025
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly- [...]
Picard Medical, Inc. Announces Closing of $17 Million Initial Public Offering
02/09/2025
TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that it closed its initial public offering of 4,250,000 shares of common stock, [...]

Pages